Frederix, E. M. A.; Kuczaj, A. K.; Nordlund, M.; Winkelmann, C.; Zinovik, I.; Geurts, B. J.
In the process of single-species homogeneous vapor condensation into aerosol, surface is created between liquid and vapor. The energy of formation of such surface limits the condensation of vapor from a supersaturated state. Nucleation, the mechanism of generation of embryo sites, or nuclei, on which vapor is able to condense, is an important process. Developing an understanding of this process is important, as it may lead to a considerable contribution to many engineering problems, as well as atmospheric and environmental science. In this work, we present an OpenFOAM®-based numerical simulation tool, which is capable of predicting aerosol formation using a two-moment representation of the aerosol and classical nucleation theory. We aim at developing a flexible utility, which enables researchers interested in various aerosol production-related applications to quickly study concepts like aerosol nucleation, condensation, diffusion and transport. We compare our numerical approach with the results of physical experiments, each using a laminar flow diffusion chamber (ref. [1, 2, 3]) with different species and/or carrier gasses. A good agreement between experimental and numerical results for the aerosol droplet number density is shown.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.